Physician profile
Alison Spangler
NPI 1679988604
$10,347.68
in general payments reported to CMS, 2019-2025
41 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $286 · 2021: $289 · 2022: $2,303 · 2023: $3,078 · 2024: $1,925 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,810.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,278.31 | 2019-2025 | Ensite, Aveir, Jot Dx |
| Pfizer INC. | $1,002.39 | 2019-2025 | |
| Boston Scientific Corporation | $863.65 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Medtronic, INC. | $820.31 | 2021-2025 | Selectsecure, Cobalt Dr Mri Surescan, Micra |
| Amgen INC. | $772.98 | 2019-2025 | Repatha |
| Philips North America LLC | $603.49 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, Mcot |
| Merck Sharp & Dohme LLC | $525.13 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.26 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $505.03 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $485.01 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $335.34 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $297.87 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $278.07 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Sanofi-Aventis U.S. LLC | $216.56 | 2022-2023 | |
| Novo Nordisk INC | $216.30 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $193.04 | 2022-2025 | |
| Biosense Webster, INC. | $177.49 | 2023 | Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter |
| Impulse Dynamics (USA) INC. | $136.90 | 2022-2023 | Optimizer |
| Inspire Medical Systems, INC. | $132.38 | 2023-2025 | Inspire |
| Heartflow, INC. | $109.26 | 2023-2024 | Ffrct |
| Irhythm Technologies, INC. | $103.26 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $97.33 | 2019-2025 | Evkeeza |
| Abiomed | $87.59 | 2024-2025 | Impella |
| Bridgebio Pharma, INC. | $69.05 | 2025 | Attruby |
| Astellas Pharma US INC | $60.45 | 2019-2021 | |
| Biotronik INC. | $48.97 | 2019 | |
| Portola Pharmaceuticals, LLC | $46.54 | 2019-2020 | |
| Terumo Medical Corporation | $45.91 | 2024-2025 | Glidewire |
| Esperion Therapeutics, INC. | $45.07 | 2022-2024 | Nexletol |
| Glaxosmithkline, LLC. | $37.91 | 2025 | Shingrix, Arexvy |
| Alnylam Pharmaceuticals INC. | $37.76 | 2025 | Amvuttra |
| Chiesi USA, INC. | $32.79 | 2021-2022 | |
| Scpharmaceuticals INC. | $32.73 | 2024 | |
| Cvrx, INC. | $29.53 | 2022-2025 | Barostim Neo System |
| Ionis Pharmaceuticals, INC. | $20.55 | 2025 | Tryngolza |
| Convatec INC. | $20.15 | 2019 | |
| Elutia, INC. | $16.86 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Baxter Healthcare | $13.84 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $13.34 | 2023 | Inpefa |
| Tactile Systems Technology INC | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.